Globenewswireยท2025-04-04 13:40Core Viewpoint - Renovaro Biosciences Inc. is facing a significant challenge following the termination of its merger agreement with Predictive Oncology, which the company claims is in breach of their binding agreements [2] Group 1: Company Overview - Renovaro Biosciences Inc. is a leader in TechBio, focusing on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies [1] - The company aims to accelerate precision and personalized medicine through AI and biotechnology platforms for early diagnosis and targeted treatments [3] Group 2: Merger Agreement Details - Renovaro entered into a binding merger agreement with Predictive Oncology on January 1, 2025, which was supplemented by an Extension Agreement on February 28, 2025 [2] - On April 3, 2025, Predictive Oncology terminated the merger transaction, leading Renovaro to assert that Predictive Oncology must comply with the binding obligations and enter into an exclusive License Agreement [2] Group 3: Legal Actions - Renovaro claims that the breach by Predictive Oncology has caused substantial damage, and the company will seek legal remedies if an exclusive License Agreement is not established by April 10, 2025 [2]